|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1993-2-11
|
|
pubmed:abstractText |
This study was undertaken to analyze the specificity and neutralizing properties of cross-reactive anti-gp120 antibodies (Abs) in the sera of two human immunodeficiency virus (HIV)-infected asymptomatic individuals. Two panels of murine monoclonal anti-idiotype Abs (anti-id MAbs) were established against cross-reactive polyclonal anti-gp120 Abs purified from HIV+ sera by sequential affinity chromatography using gp120SF2- and gp120IIIB-Sepharose columns. These panels of anti-id MAbs were then used to affinity purify idiotype-positive (Id+) anti-gp120 Abs from HIV+ sera. The recovery of each of these Id+ Abs by purification indicated that several idiotypically distinct cross-reactive anti-gp120 Abs are present in sera over a wide range of concentrations. Immunological and biological studies showed that although all of the Id+ Abs were reactive against gp120SF2 and gp120IIIB, they exhibited unique epitope specificities and distinct neutralizing activities. Most of the Id+ Abs were directed against epitopes in the CD4 attachment site (CD4 site epitopes) of gp120 and exhibited a spectrum of broadly neutralizing activities. On the other hand, a minor population of Id+ Abs showed specificity for the V3 region of gp120 and exhibited limited cross-neutralizing activities. Together, these studies indicate that the CD4 site epitope-specific Abs are heterogeneous with respect to their clonality, neutralizing activity, and concentration in sera. This heterogeneity suggests that anti-gp120 Abs to the CD4 attachment site are developed in response to multiple overlapping epitopes present on the original virus isolate and/or epitopes on mutated variants which emerged over time.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1378015,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1378074,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-13940767,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1557358,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1622892,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1683006,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1702163,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1703322,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1710248,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1717712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1717717,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1717992,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1718036,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1724568,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1726397,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-17837506,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1920632,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-1961739,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-2068099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-2122456,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-2243375,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-2304000,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-2370681,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-2451922,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-2452899,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-2454471,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-2456088,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-3281026,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-3392769,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-3405290,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-3487551,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-3629244,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7678311-6187005
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0022-538X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
953-60
|
|
pubmed:dateRevised |
2010-9-10
|
|
pubmed:meshHeading |
pubmed-meshheading:7678311-Amino Acid Sequence,
pubmed-meshheading:7678311-Antibodies, Anti-Idiotypic,
pubmed-meshheading:7678311-Antibodies, Monoclonal,
pubmed-meshheading:7678311-Antigens, CD4,
pubmed-meshheading:7678311-Cross Reactions,
pubmed-meshheading:7678311-Epitopes,
pubmed-meshheading:7678311-Genetic Variation,
pubmed-meshheading:7678311-HIV Antibodies,
pubmed-meshheading:7678311-HIV Envelope Protein gp120,
pubmed-meshheading:7678311-HIV Seropositivity,
pubmed-meshheading:7678311-HIV-1,
pubmed-meshheading:7678311-Humans,
pubmed-meshheading:7678311-Molecular Sequence Data,
pubmed-meshheading:7678311-Neutralization Tests
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals.
|
|
pubmed:affiliation |
IDEC Pharmaceuticals Corporation, La Jolla, California 92037.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
